Abstract: Disclosed is an infusion preparation for nutrient supply use. It comprises a sugar, amino acids, electrolytes and a fat emulsion. It has an excellent shelf life without causing precipitation, denaturation and the like in spite of the simultaneous presence of these components. Also disclosed is a container filled with infusion liquids comprising a first and a second compartments separated from each other by a separation means, wherein an infusion liquid containing a fat emulsion and a sugar is included in the first compartment and another infusion liquid containing amino acids and electrolytes is included in the second compartment. Further disclosed are an infusion preparation comprising a fat emulsion and a sugar, and an infusion preparation comprising amino acids and electrolytes.

Abstract: The process for producing the albumin preparation of the present invention comprises treating an aqueous albumin solution with an anion exchanger and a cation exchanger and subjecting the solution to heat treatment wherein a polyacrylamide type carrier having a cation exchange group is used as a cation exchanger. By using a polyacrylamide type carrier as a cation exchanger, the polymerization caused by the contaminating proteins can be suppressed, and a highly purified albumin preparation can be obtained.

Abstract: A process for producing recombinant human serum albumin is disclosed, which comprises culturing a human serum albumin-producing host, prepared by gene manipulation techniques in a medium that contains an amino acid, preferably at least one amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, histidine, serine, tryptophan, valine, isoleucine, phenylalanine, cysteine and arginine, more preferably histidine. The process can significantly increase the yield of human serum albumin over that produced by known processes.

Abstract: A mutant AOX2 (alcohol oxidase 2) promoter derived from the natural AOX2 promoter by base sequence deletion, insertion, or substitution is disclosed. A microbial strain carrying a gene under the control of such a mutant AOX2 promoter can be obtained by growing in a methanol-containing medium a strain incapable of producing AOX encoded by the AOX1 gene but carrying the AOX2 gene under the control of the natural AOX2 promoter. A heterologous protein may be produced by cultivating the mutant strain with the desired heterologous protein gene incorporated downstream from the mutant AOX2 promoter. A plasmid carrying the mutant AOX2 promoter is also provided.

Abstract: The orally administrable pharmaceutical compositions containing a slightly water-soluble drug, characterized by improved stability and improved absorption of the drug from digestive tract into blood. The use of the compositions of the present invention enables decrease of the dose amount of a slightly water-soluble drug, which eventually leads to alleviation of pains and side effects on the part of patients.

Abstract: A liquid preparation of antithrombin-III (AT-III), comprising an AT-III and an organic acid, a salt thereof, a sugar sulfate or a surfactant as a stabilizer, and a liquid preparation of AT-III, having a pH of 9-10. The preparation of the present invention is stable after long-term preservation and poses no clinical problems in terms of pharmacological effects and safety. The preparation is more advantageous than lyophilized preparations in that it does not require dissolution in injectable distilled water and can be used easily. Accordingly, the preparation is clinically very useful.

Abstract: An unprocessed human immunodeficiency virus 2 (HIV-2) gag precursor protein, containing a deficient protease, assembles into virus-like particles by budding through the cytoplasmic domain of baculovirus-infected cells. Chimeric constructs were generated by coupling the truncated HIV-2 gag gene to the neutralizing domain (V3) or the neutralizing and CD4 binding domains (V3+CD4B) of gp120 env gene sequences obtained from HIV-1 or HIV-2. Virus-like particles were formed by chimeric gene products when the env gene sequences were linked to the 3' terminus of the gag gene. The gag-env chimeric proteins displayed immunoreactivity towards anti-gp120 rabbit antisera.

Abstract: A compound of the following formula ##STR1## wherein m is an integer of 1 to 3, R.sub.1 and R.sub.2 are the same or different and each is hydrogen atom or lower alkyl, and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are the same or different and each is hydroxy or a group of the formula ##STR2## (wherein n is 0 or 1, X is --NH-- or --O--, Y is alkylene, A is hydrogen atom, lower alkyl, lower alkoxy, halogen atom or trifluoromethyl, and B is alkyl or alkenyl), with the proviso that two or three of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are hydroxyl groups and that when two of them are hydroxyl groups, the cases where R.sub.3 and R.sub.5 are hydroxy, and R.sub.4 and R.sub.6 are hydroxy are excluded; a complex compound comprising said compound and a metallic atom; and a diagnostic agent containing said complex compound. The above compound is useful as a chelating agent and the complex compound comprising said compound and a metallic atom exhibits superior characteristics as a contrast medium for image diagnosis.

Abstract: An self-adhesive article which is produced by forming an adhesive layer from an adhesive consisting essentially of a polymer of which is soluble in or swellable by an iso-thiocyanate, impregnating the adhesive layer with an iso-thiocyanate to provide a biocidal self-adhesive, and applying the biocidal self-adhesive to at least one surface of a base material. A high concentration of the iso-thiocyanate can be held in the adhesive layer, and the self-adhesive article is put to uses intended for the purpose of providing bactericidal, fungicidal and microbiocidal effects in building and food-related fields and the like.

Abstract: A quinoline-3-acetic acid derivative of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom or a substituted or unsubstituted lower alkyl, R.sup.5 is an optionally esterified carboxyl and the broken line means an optional presence of a double bond, and a pharmaceutically acceptable salt thereof. The novel compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and are highly safe. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.

Abstract: Production of a benzothiazole compound of the formula (I) ##STR1## wherein R.sup.1 is a halogen atom, R.sup.2 and R.sup.3 may be the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom, a lower alkyl, an alkoxy or an alkyl mercapto and R.sup.5 is a hydrogen atom or a lower alkyl, or a pharmaceutically acceptable salt thereof.The compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and have superior safety. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.

Abstract: A novel pharmaceutical use of a dihydropyridine derivative of the formula (I) ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and each is an alkyl or the like; R.sub.4 is a hydrogen atom or the like; R.sub.5 is nitro, a halogenated alkyl, cyano or the like; X is a vinylene or an azomethine; A is an alkylene; and B is --N(R.sub.6) (R.sub.7) or a group of the formula ##STR2## wherein R.sub.6 and R.sub.7 are the same or different and each is an alkyl, an aralkyl, an aryl or the like; R.sub.8 and Ar are aryl or the like; and n is 0, 1 or 2, or an acid addition salt thereof for promoting PGI.sub.2 production, and for the treatment and prevention of hyperlipemia, arteriosclerosis and cerebral diseases.

Abstract: Human serum albumin obtained by gene manipulation techniques can be purified by a combination of specified steps in which a culture supernatant obtained from a human serum albumin-producing host is subjected to ultrafiltration, heat treatment, acid treatment and another ultrafiltration, followed by subsequent treatments with a cation exchanger, a hydrophobic chromatography carrier and an anion exchanger, and by salting-out to thereby obtain a pure form of human serum albumin which contains substantially no proteinous and polysaccharide contaminants, which is formulated into a pharmaceutical preparation. The thus obtained human serum albumin can further be purified by treating recombinant human serum albumin with a hydrophobic chromatography carrier at pH of 2 to 5 and a salt concentration of 0.4 to 1 and exposing the carrier to a pH of 6 to 8 and a salt concentration of 0.01 to 0.

Abstract: A method for preparing foreign protein in yeast using an expression recombinant DNA comprising DNA encoding the serum albumin signal peptide adjacent to DNA encoding the foreign protein is disclosed.

Abstract: A pharmaceutical preparation for rectal or vaginal administration, comprising a prostaglandin compound and an alkali metal salt of a fatty acid having 8 to 12 carbon atoms, and a method for administering a prostaglandin compound, comprising rectally or vaginally administering same in the presence of an alkali metal salt of a fatty acid.According to the present invention, absorption of prostaglandin from rectum or vagina can be enhanced.The prostaglandin can be stabilized in the preparation.

Abstract: A quinoline compound represented by the formula (1) or a salt thereof: ##STR1## wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.

Abstract: The orally administrable pharmaceutical compositions containing a slightly water-soluble drug, characterized by improved stability and improved absorption of the drug from digestive tract into blood. The use of the compositions of the present invention enables decrease of the dose amount of a slightly water-soluble drug, which eventually leads to alleviation of pains and side effects on the part of patients.

Abstract: A compound of the following formula ##STR1## wherein m is an integer of 1 to 3, R.sub.1 and R.sub.2 are the same or different and each is hydrogen atom or lower alkyl, and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are the same or different and each is hydroxy or a ##STR2## (wherein n is 0 or 1, X is --NH-- or --O--, Y is alkylene, A is hydrogen atom, lower alkyl, lower alkoxy, halogen atom or trifluoromethyl, and B is alkyl or alkenyl), with the proviso that two or three of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are hydroxyl groups and that when two of them are hydroxyl groups, the cases where R.sub.3 and R.sub.5 are hydroxy, and R.sub.4 and R.sub.6 are hydroxy are excluded; a complex compound comprising said compound and a metallic atom; and a diagnostic agent containing said complex compound. The above compound is useful as a chelating agent and the complex compound comprising said compound and a metallic atom exhibits superior characteristics as a contrast medium for image diagnosis.

Abstract: An angiographic adjuvant comprising a fat emulsion containing a compound having prostaglandin E1 activities, and an angiographic method using the adjuvant.

Abstract: The chimeric proteins, and a protential vaccine and diagnostic reagent comprising gag-env chimeric protein particles are disclosed. The preparation comprises linking gag of HIV-2 to env to form the chimeric gene, inserting the obtained chimeric gene into the DNA of a baculovirus, infecting insect cells or insect host with the resulting recombinant virus, culturing it and purifying the obtained chimeric protein. The gag chimeric protein of HIV according to the present invention retains both antigenic and immunogenic properties.